The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - EUSA Pharma
Travel, Accommodations, Expenses - Otonomy
Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors.
 
Ami Vijay Desai
No Relationships to Disclose
 
Garrett M. Brodeur
No Relationships to Disclose
 
Jennifer Foster
No Relationships to Disclose
 
Stacey L. Berg
Research Funding - Other (Inst)
 
Ellen M. Basu
No Relationships to Disclose
 
Suzanne Shusterman
No Relationships to Disclose
 
Amit J. Sabnis
No Relationships to Disclose
 
Margaret Macy
Stock and Other Ownership Interests - Johnson & Johnson; Varian Medical Systems
Speakers' Bureau - Ventana Medical Systems
 
Janet Yoon
No Relationships to Disclose
 
Karen Gauvain
No Relationships to Disclose
 
Vanessa Esquibel
Employment - Ignyta
Stock and Other Ownership Interests - Ignyta
 
Edna Chow Maneval
Employment - Ignyta
Stock and Other Ownership Interests - Ignyta
 
Pratik S. Multani
Employment - Ignyta
Leadership - Ignyta
Stock and Other Ownership Interests - Ignyta
 
Elizabeth Fox
Research Funding - Ignyta (Inst)
Travel, Accommodations, Expenses - Helsinn Therapeutics
Other Relationship - Helsinn Therapeutics